Oncorus Inc
ONCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $48.03 Million |
| Dividend Yield | $0.14 (110.58%) |
| Earnings per Share | $-3.02 |
| Beta | 1.95 |
| Outstanding Shares | 26,095,000 |
Return
| Return on Equity | -302.90% |
|---|---|
| Return on Assets | -85.89% |
| Return on Invested Capital | -75.37% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | 0.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.81 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.44 |
| Debt to Equity | 2.23 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Oncorus Inc
56 employeesAt Oncorus, the company is focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. Oncorus is advancing a portfolio of intratumorally and intravenously administered viral ...